Michael Schmitz
Stock Analyst at Guggenheim
(2.99)
# 1,333
Out of 5,132 analysts
8
Total ratings
85.71%
Success rate
54.31%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Michael Schmitz
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ERAS Erasca | Maintains: Buy | $3 → $5 | $12.00 | -58.33% | 1 | Nov 14, 2025 | |
| GMAB Genmab | Upgrades: Buy | $43 | $30.03 | +43.19% | 1 | Sep 24, 2025 | |
| EXEL Exelixis | Reiterates: Buy | $45 | $43.92 | +2.46% | 1 | Jul 29, 2025 | |
| RVMD Revolution Medicines | Maintains: Buy | $72 → $82 | $96.31 | -14.86% | 2 | Oct 28, 2024 | |
| ARVN Arvinas | Upgrades: Buy | $40 | $11.65 | +243.35% | 1 | Nov 20, 2023 | |
| FATE Fate Therapeutics | Downgrades: Neutral | n/a | $1.25 | - | 1 | Jan 3, 2023 | |
| APC ARKO Petroleum | Initiates: Buy | $85 | $18.00 | +372.22% | 1 | Dec 19, 2016 |
Erasca
Nov 14, 2025
Maintains: Buy
Price Target: $3 → $5
Current: $12.00
Upside: -58.33%
Genmab
Sep 24, 2025
Upgrades: Buy
Price Target: $43
Current: $30.03
Upside: +43.19%
Exelixis
Jul 29, 2025
Reiterates: Buy
Price Target: $45
Current: $43.92
Upside: +2.46%
Revolution Medicines
Oct 28, 2024
Maintains: Buy
Price Target: $72 → $82
Current: $96.31
Upside: -14.86%
Arvinas
Nov 20, 2023
Upgrades: Buy
Price Target: $40
Current: $11.65
Upside: +243.35%
Fate Therapeutics
Jan 3, 2023
Downgrades: Neutral
Price Target: n/a
Current: $1.25
Upside: -
ARKO Petroleum
Dec 19, 2016
Initiates: Buy
Price Target: $85
Current: $18.00
Upside: +372.22%